physiolog
process
fact
mani
differ
system
complex
carbohydr
common
theme
given
rise
term
glycobiolog
defin
studi
structur
function
carbohydr
modif
differ
type
macromolecul
complex
carbohydr
found
attach
protein
lipid
glycoprotein
produc
eucaryot
cell
either
nlink
oligosaccharid
olink
oligosaccharid
frequent
type
structur
found
protein
addit
number
oligosaccharid
chain
attach
protein
vari
one
mani
chain
nlink
type
describ
detail
carbohydr
attach
amid
nitrogen
asparagin
residu
occur
tripeptid
sequenc
asnxser
thr
howev
sequon
suffici
glycosyl
occur
sinc
mani
asnxser
thr
sequenc
found
pro
tein
glycosyl
appear
conform
protein
around
sequenc
perhap
exposur
critic
factor
addit
carbohydr
hand
common
type
olink
structur
mucin
oligosac
charid
attach
oglycosid
bond
usual
involv
galnac
link
oh
group
serin
threonin
residu
known
amino
acid
sequenc
necessari
glycosyl
term
lipid
best
known
common
type
glycolipid
sphingolipid
contain
oligosaccharid
chain
com
pose
follow
sugar
glucos
galactos
glcnac
galnac
sialic
acid
fucos
sugar
may
present
variou
configur
combin
link
ceramid
made
fatti
acid
sphingosin
compound
consider
import
medicin
sinc
certain
gangliosid
shown
receptor
diphtheria
cholera
toxin
cerebrosid
involv
bacteri
attach
anim
cell
sinc
number
current
review
cover
compound
detail
consid
recent
de
scribe
type
glycolipid
glycosyl
phosphatidylinositol
gpi
type
glycan
mannos
glcnac
sometim
sugar
galactos
attach
membran
phospholipid
phosphati
dylinositol
gpi
molecul
appear
import
anchor
mani
protein
membran
inhibitor
nlink
oligosaccharid
assembl
also
affect
synthesi
glycan
portion
anchor
consid
detail
later
section
although
consider
amount
inform
avail
concern
ing
structur
nlink
oligosaccharid
gpi
glycan
rel
littl
data
concern
function
carbohydr
portion
molecul
appear
protein
lipid
glycosyla
tion
two
major
role
modul
chang
biochem
proper
tie
molecul
includ
paramet
bioactiv
fold
ing
stabil
turnov
immunoreact
serv
determin
molecular
recognit
event
lysosom
enzym
target
parasit
symbiot
bind
adhes
host
cell
attach
toxin
biolog
import
ligand
cell
surfac
case
somewhat
difficult
demonstr
func
tional
role
carbohydr
portion
glycoprotein
one
obviou
way
would
obtain
particular
glycoprotein
without
carbohydr
compar
biolog
biochem
prop
erti
unglycosyl
form
normal
glycoprotein
number
way
produc
glycoprotein
without
associ
carbohydr
especi
case
nlink
glycopro
tein
exampl
one
remov
nlink
oligosaccharid
endoglycosidas
endoglucosaminidas
h
endo
h
cleav
highmannos
oligosaccharid
two
intern
glcnac
residu
peptid
glycosidas
f
hydrolyz
nlink
oligosaccharid
glcnac
asparagin
bond
problem
approach
mani
nlink
oligosaccharid
resist
cleavag
enzym
protein
nativ
state
therefor
necessari
denatur
protein
order
obtain
complet
remov
nlink
oligosaccharid
make
method
unten
function
studi
anoth
problem
approach
remov
carbohydr
protein
synthes
achiev
proper
conform
may
quit
differ
physiolog
protein
synthes
cell
absenc
carbohydr
second
possibl
produc
glycoprotein
interest
cell
system
presenc
antibiot
tunicamycin
compound
inhibit
transferas
catalyz
first
step
dolichol
cycl
therebi
prevent
format
lipidlink
oligosaccharid
inhibit
usual
result
com
plete
blockag
nlink
glycosyl
difficulti
approach
mani
glycoprotein
may
improperli
fold
come
insolubl
synthes
without
nlink
carbo
hydrat
result
physiolog
studi
becom
question
valu
third
altern
prevent
glycosyl
use
sitedirect
mutagenesi
modifi
asnxser
sequon
glycosyl
one
nonacceptor
sequon
beauti
method
one
modifi
one
glycosyl
site
time
assum
one
determin
alter
site
affect
function
one
modifi
number
site
time
compar
variou
protein
two
potenti
obstacl
gene
code
protein
interest
must
avail
one
must
make
assumpt
chang
amino
acid
sequenc
affect
protein
conform
methodol
ogi
provid
valuabl
insight
role
asparaginelink
glycosyl
howev
nlink
oligosaccharid
sequon
modifi
problem
improp
fold
solubl
one
find
tunicamycin
would
also
appli
anoth
possi
biliti
modifi
glycosyl
rather
prevent
result
nlink
glycoprotein
contain
alter
oligosaccharid
structur
one
determin
alter
affect
biolog
activ
given
glycoprotein
sever
way
modifi
nlink
oligosaccharid
structur
exampl
protein
interest
produc
mutant
cell
line
defect
one
biosynthet
enzym
cell
line
miss
variou
glycosyltransferas
process
glycosidas
isol
sever
excel
review
describ
variou
mutant
techniqu
util
case
also
one
must
gene
glycoprotein
interest
order
introduc
mutant
cell
line
synthesi
appropri
protein
carbohydr
structur
also
modifi
select
inhibi
tor
block
activ
key
enzym
process
pathway
synthesi
stop
prematur
step
variou
type
complex
chain
form
inhibitor
site
action
main
topic
chapter
one
disadvantag
use
inhibitor
vivo
studi
nlink
glycoprotein
affect
therefor
may
difficult
relat
chang
physiolog
effect
specif
glycoprotein
interest
fact
one
critic
levi
use
inhibitor
biolog
system
also
chemotherapeut
agent
absolut
specif
iti
seldom
ever
achiev
cours
case
alter
glycoprotein
isol
inhibit
mutat
cell
activ
compar
normal
protein
either
vitro
anoth
system
critic
overcom
one
final
method
alter
carbohydr
structur
disrupt
alter
normal
transport
glycoprotein
er
variou
golgi
stack
ultim
locat
sinc
clear
certain
oligosaccharid
trim
reaction
occur
er
wherea
other
occur
cisgolgi
still
other
medial
golgi
etc
basi
approach
prevent
protein
transport
region
enzymat
activ
locat
one
somehow
prevent
glycoprotein
reach
specif
compart
hous
activ
reaction
occur
sever
valuabl
compound
properti
drug
discuss
later
section
type
inhibitor
extrem
use
tool
help
us
understand
mechan
protein
target
term
glycan
portion
gpi
anchor
number
recent
studi
demonstr
variou
inhibitor
act
link
oligosaccharid
also
inhibit
reaction
anchor
format
inhibitor
provid
use
inform
biosynthet
pathway
also
help
function
studi
howev
stage
still
know
enough
synthesi
glycan
portion
gpi
anchor
realli
understand
function
chapter
deal
variou
type
inhibitor
affect
gpi
anchor
format
well
act
link
glycoprotein
ii
common
type
glycoprotein
present
eucaryot
cell
cell
surfac
protein
membran
protein
secretori
protein
oligosaccharid
attach
amid
nitro
gen
asparagin
nlink
asparaginelink
oligosac
charid
portion
molecul
may
varieti
differ
structur
fall
one
gener
group
shown
fig
refer
highmannos
complex
hybrid
type
oligosaccharid
seen
figur
structur
contain
basic
core
region
shown
boxedin
area
compos
oligosaccharid
sequenc
man
highmannos
structur
core
region
elong
mani
six
addit
mannos
residu
ie
total
nine
mannos
unit
attach
linkag
shown
typic
structur
present
fig
howev
highmannos
oligosaccharid
may
fewer
six
addit
mannos
sinc
trim
occur
biosynthesi
see
section
v
hand
complex
type
oligosaccharid
pentasaccharid
core
region
extend
number
differ
substitut
shown
figur
typic
biantennari
type
oligosaccharid
contain
two
trisaccharid
sequenc
hand
complex
chain
may
three
triantennari
four
tetraantennari
trisaccharid
sequenc
well
variou
substitut
lfucos
innermost
glcnac
sulfat
residu
attach
glcnac
variou
alter
may
also
occur
fucos
unit
outer
glcnac
residu
polylactosamin
chain
glcnac
residu
attach
mannos
well
variou
glycosid
linkag
sialic
acid
rather
sialic
acid
etc
although
exact
number
differ
type
complex
chain
clear
estim
probabl
sever
hundr
known
structur
final
type
nlink
oligosaccharid
hybrid
structur
still
contain
branch
arm
also
type
complex
chain
hybrid
chain
also
apparantli
bisect
glcnac
attach
mannos
substitut
may
play
role
control
process
reaction
biosynthesi
nlink
oligosaccharid
involv
two
independ
sequenti
pathway
occur
endo
plasmic
reticulum
er
golgi
apparatu
cell
first
seri
reaction
membran
secretori
protein
go
synthesi
membranebound
polysom
becom
glycosi
late
transfer
common
oligosaccharid
structur
glc
man
glcnac
lipidlink
saccharid
form
ie
glc
man
glcnac
ppdolichol
specif
asnxser
thr
sequenc
protein
pathway
refer
dolichol
cycl
depict
fig
seri
glycosyltransferas
associ
er
membran
sequenti
add
sugar
glcnac
mannos
glucos
lipid
carrier
dolichylp
give
abovement
lipidlink
oligosaccharid
donor
studi
pathway
anim
cell
cultur
system
one
add
one
radioact
sugar
ie
h
glucosamin
h
galactos
tag
glucos
residu
h
mannos
medium
examin
incorpor
label
lipidlink
saccharid
intermedi
easi
extract
cell
sequenti
extract
procedur
first
ch
h
ex
tract
lipidlink
monosaccharid
smaller
size
lipidlink
oligosaccharid
extract
remain
residu
ch
h
obtain
lipidlink
oligosaccharid
contain
larger
size
oligosaccharid
intact
lipidlink
monosaccharid
usual
identifi
tlc
wherea
larger
oligosaccharid
lipidlink
oligosaccharid
usual
leas
mild
acid
hydrolysi
character
gel
filtrat
biogel
hplc
thu
first
enzym
biosynthesi
nlink
oligosaccha
ride
transfer
glcnaclp
udpglcnac
dolichylp
form
dolichylppglcnac
enzym
site
action
wide
use
glycosyl
inhibitor
tunicamycin
discuss
later
transferas
purifi
homogen
bovin
mammari
gland
gene
enzym
recent
clone
express
co
cell
next
glcnac
transferas
add
second
glcnac
also
udpglcnac
dolichylppglcnac
form
en
zyme
recent
purifi
homogen
pig
aorta
next
five
sugar
ad
mannos
residu
nate
via
gdpmannos
indic
two
line
evid
demonstr
gdpmannos
rather
dolichylpmannos
mannosyl
donor
addit
mutant
cell
line
miss
dolichylpmannos
synthas
still
form
man
abl
elong
b
amphomycin
inhibitor
vitro
format
dolichylpmannos
prevent
format
man
glcnac
ppdolichol
block
elong
intermedi
transferas
add
first
mannos
dolichol
inter
mediat
recent
purifi
homogen
pig
aorta
azidolabel
p
gdpmannos
use
identifi
subunit
protein
sever
also
partial
purifi
liver
enzym
requir
gdpmannos
rather
dolichylpmannos
manno
syl
donor
howev
protein
yet
purifi
homo
geneiti
detail
properti
orient
er
membran
known
man
glcnac
ppdolichol
form
glycosyl
addit
four
mannos
residu
three
glucos
unit
mannos
residu
believ
donat
via
dolichylpmannos
topolog
oligosac
charid
er
lumen
result
mutant
miss
dolichylpmannos
synthas
wherea
glucosyl
donor
dolichylpglucos
enzym
isol
studi
detail
therefor
littl
known
properti
howev
enzym
add
first
mannos
dolichylpmannos
ie
sixth
mannos
lipid
par
tialli
purifi
aorta
extract
substrat
specif
determin
activ
enzym
requir
dolichylpmannos
mannosyl
donor
man
glcnac
ppdolichol
mannosyl
acceptor
likewis
enzym
add
first
glucos
dolichylpglucos
man
glcnac
ppdolichol
purifi
near
homogen
pig
aorta
substrat
specif
oligosac
charid
acceptor
specif
determin
number
oligo
saccharid
structur
link
dolichol
could
serv
glucos
ac
ceptor
requir
activ
enzym
add
last
two
glucos
yet
purifi
role
glucos
unit
biosynthesi
nlink
oligosac
charid
presum
facilit
transfer
oligosaccharid
lipid
protein
oligosaccharyltransferas
catalyz
final
step
dolichol
cycl
recogn
prefer
glucosecontain
lipidlink
oligosaccharid
oligosaccharid
donor
fact
studi
microsom
show
glucosecontain
lipidlink
oligosaccharid
much
effici
oli
gosaccharid
donor
glucosefre
lipidlink
oligosaccha
ride
thu
last
step
dolichol
cycl
occur
er
oligosaccharid
transfer
specif
asparagin
residu
protein
polypeptid
elong
erbound
poli
some
oligosaccharyltransferas
recent
purifi
appar
homogen
liver
oligosaccharid
chain
transfer
protein
protein
still
undergo
synthesi
er
two
membranebound
highli
specif
glucosidas
remov
three
glucos
glc
man
glcnac
process
pathway
link
oligosaccharid
outlin
fig
thu
glucosidas
move
outermost
glucos
give
glc
man
glcnac
protein
wherea
glucosidas
ii
remov
next
two
glucos
give
man
glcnac
protein
glucosi
dase
purifi
calf
porcin
liver
bovin
mammari
gland
mung
bean
seedl
saccharomyc
cerevesia
enzym
ph
optimum
neutral
rang
work
pnitrophenyladglucopyranosid
quit
specif
linkag
mam
malian
enzym
tetram
subunit
kda
wherea
yeast
enzym
subunit
kda
cerevesia
glsl
mutat
result
cell
lack
glucosidas
produc
glyco
protein
maintain
glc
man
glcnac
structur
ever
alter
structur
effect
secret
glyco
protein
contrast
mammalian
cell
alter
profound
effect
see
section
glucosidas
inhibitor
cho
mutant
cell
line
isol
virtu
resist
lpha
mutant
cell
call
shown
lack
glucosidas
cell
found
synthes
g
protein
vsv
hybrid
highmannos
oligosaccharid
well
complex
chain
glucosidas
ii
initi
identifi
microsom
fraction
rat
liver
calf
liver
yeast
shown
move
glucos
glc
man
glcnac
form
man
glcnac
howev
remov
outermost
glucos
quit
rapid
min
compar
cleavag
innermost
glucos
min
although
glucosidas
ii
also
catalyz
cleavag
arylaglucosid
pnitrophenylaglucopyranosid
appear
fairli
specif
glucos
sinc
activ
inhibit
glucos
disaccharid
nigeros
glucos
disaccharid
ie
kojibios
maltos
isomaltos
trehalos
glucosidas
ii
pig
kidney
port
subunit
molecular
mass
kda
highmannos
glycoprotein
wherea
enzym
mung
bean
compos
two
ident
glycoprotein
subunit
kda
also
high
mannos
oligosaccharid
probabl
also
contain
glucos
residu
anim
system
howev
glucosidas
ii
quit
differ
subunit
molecular
weight
around
kda
local
enzym
also
studi
may
vari
depend
tissu
concentr
rough
er
rer
smooth
er
ser
pig
hepatocyt
postgolgi
apparatu
structur
pig
kidney
tubular
cell
best
substrat
assay
process
glucosidas
radiolabel
glc
man
glcnac
glc
man
glcnac
substrat
prepar
incub
anim
cell
virusinfect
cell
presenc
process
inhibitor
castanospermin
discuss
later
prevent
remov
glucos
residu
deoxymannojirimycin
prevent
remov
mannos
h
galactos
ad
cell
cultur
label
glucos
moieti
newli
synthes
glycoprotein
glycopeptid
result
pronas
digest
glycoprotein
isol
gel
filtrat
column
biogel
glycopeptid
treat
endo
h
obtain
h
glucos
label
glc
man
glcnac
oligo
saccharid
treat
glucosidas
prepar
free
glucosidas
ii
obtain
h
glc
man
glc
nac
assay
process
glucosidas
activ
previous
mention
radiolabel
substrat
incub
appropri
enzym
prepar
releas
label
glucos
measur
concanavalin
asepharos
bind
assay
remov
three
glucos
residu
glc
man
glc
nac
protein
result
format
highmannos
man
glcnac
protein
process
highmannos
complex
type
oligosaccharid
seen
fig
earli
studi
process
pathway
indic
two
three
neutral
activ
involv
trim
nlink
oligosaccharid
activ
distinct
lysosom
result
increas
interest
area
research
number
new
activi
tie
describ
current
work
aim
tri
stand
variou
enzym
function
remov
mannos
eucaryot
cell
glycoprotein
fact
one
im
portant
reason
number
specif
mannosidas
inhibitor
see
section
v
abl
use
distinguish
among
variou
mannosidas
activ
well
determin
happen
pro
cess
function
given
glycoprotein
specif
amannosidas
inhibit
wellwritten
review
deal
variou
amannosidas
enzym
briefli
cover
er
remov
singl
man
nose
man
glcnac
give
specif
man
glcnac
isom
purifi
yeast
enzym
inhibit
pro
cess
inhibitor
deoxymannojirimycin
requir
ca
activ
work
arylamannosid
gene
enzym
isol
code
protein
three
nglycosyl
site
ca
bind
consensu
sequenc
noncleav
signal
sequenc
near
terminu
act
transmembran
type
ii
domain
ca
requir
also
puri
fie
rabbit
liver
enzym
show
consider
homolog
ident
similar
yeast
enzym
howev
rabbit
liver
enzym
remov
mannos
man
glcnac
requir
either
nonion
deter
gent
phospholipid
activ
two
ca
requir
amannosidas
purifi
calf
pig
liver
enzym
differ
rabbit
enzym
properti
enzym
also
work
arylamannopyranosid
substrat
pig
liver
enzym
local
immunolog
techniqu
found
distribut
rer
ser
transit
ele
ment
rer
vesicl
engag
transport
er
golgi
golgi
actual
first
neutral
report
name
mannosidas
enzym
isol
golgi
apparatu
eucaryot
cell
catalyt
properti
similar
ca
depend
mannosidas
apparantli
need
ca
although
certain
requir
test
presenc
edta
mannosidas
resolv
two
distinct
protein
chromatograph
meth
od
two
form
term
mannosidas
ia
ib
ia
purifi
homogen
shown
tetram
compos
kda
glycoprotein
subunit
presum
ia
ib
similar
substrat
specif
clear
deriv
gene
four
mannos
unit
remov
medial
golgi
glcnac
transferas
call
glcnac
transferas
add
glcnac
udpglcnac
mannos
attach
mannos
al
glcnac
transferas
purifi
homogen
liver
enzym
sequenc
clone
glcnac
apparantli
recognit
signal
anoth
highli
specif
call
mannosidas
ii
cleav
mannos
glcnacman
glcnac
protein
give
spite
substrat
specif
mannosidas
ii
act
arylamannopyranosid
pnitrophenyladmannopyranosid
mannosidas
ii
purifi
homogen
rat
liver
mung
bean
seedl
enzym
migrat
sd
gel
protein
kda
although
sequenc
murin
enzym
predict
mw
kda
deglycosyl
protein
enzym
also
glycoprotein
murin
enzym
shown
type
ii
transmembran
glycoprotein
singl
transmembran
region
lumin
orient
catalyt
site
sever
distinct
enzym
base
sensit
process
inhibitor
catalysi
highmannos
oligosaccharid
howev
rel
role
enzym
glycoprotein
process
pathway
remain
establish
one
enzym
cytosol
neutral
amannosidas
rat
liver
although
origin
thought
enzym
proteolyt
product
er
amannosidas
appear
cytosol
er
relat
isol
rat
brain
cleav
mannos
residu
last
enzym
cleav
man
glcnac
structur
man
glcnac
differ
er
liver
enzym
brain
enzym
former
enzym
also
activ
arylamannosid
wherea
latter
two
cleav
mannos
purifi
rat
sperm
rat
liver
anoth
type
hydrolyt
enzym
also
propos
involv
process
endoamannosidas
cleav
disaccharid
glc
man
glcnac
glc
man
glc
man
glcnac
etc
interest
note
man
glcnac
result
action
enzym
differ
isom
man
glcnac
form
action
er
yeast
endomannosidas
appear
resid
golgi
apparatu
may
function
trim
oligosaccha
ride
glycoprotein
escap
er
still
retain
one
glucos
residu
shown
fig
follow
trim
glucos
residu
number
mannos
unit
nlink
oligosaccha
ride
variou
glycosyltransferas
act
add
differ
sugar
glcnac
galactos
sialic
acid
fucos
etc
core
nlink
struc
ture
form
mani
differ
type
complex
chain
sinc
inhibitor
avail
glycosyltransferas
consid
review
glycosyl
phosphatidylinositol
recent
discov
class
glycolipid
shown
anchor
mani
protein
mole
cule
heparan
sulfat
biolog
membran
via
coval
linkag
recent
chemic
natur
molecul
deduc
complet
structur
still
elucid
anchor
character
glycolipid
involv
composit
analys
use
gcm
combin
specif
chemic
treatment
sequenti
digest
exoglycosidas
analysi
glycosid
linkag
methyl
analys
gel
filtra
tion
tlc
intact
glycan
degrad
product
best
known
thoroughli
detail
gpi
anchor
trypanosoma
brucei
rat
although
structur
show
differ
conserv
linear
region
shown
gener
structur
glycosylphosphatidylinositol
serv
mem
brane
anchor
mani
cell
surfac
protein
fig
compos
l
case
variabl
surfac
antigen
ie
vsg
trypanosom
number
galactos
residu
attach
first
mannos
wherea
may
galnac
andor
ethanolaminep
attach
mannos
also
structur
may
differ
number
fatti
acid
resi
due
attach
inositol
also
structur
fatti
acid
although
detail
biosynthesi
glycan
portion
anchor
known
still
consider
gap
understand
pathway
nevertheless
step
biosynthesi
propos
occur
outlin
fig
sequenc
begin
transfer
glcnac
udpglcnac
phosphatidylinositol
form
glcnacpi
undergo
deacetyl
form
glcnpi
reaction
demonstr
vivo
label
studi
hglucosamin
cellfre
extract
incub
udpglcnac
three
mannos
residu
ad
glcnpi
mannos
propos
deriv
dolichylpmannos
rather
gdpmannos
see
section
ix
experiment
evid
none
enzym
purifi
virtual
noth
known
sugar
gal
glcnac
ad
addit
clear
biosynthet
pathway
fatti
acid
ad
pi
although
evid
glcnpi
must
acyl
serv
acceptor
first
mannos
mannos
unit
ad
phosphatidylethanolamin
serv
donor
ethanolaminep
becom
attach
via
phosphodiest
bond
posit
termin
mannos
signal
gpi
addit
nascent
protein
resid
short
hydrophob
carboxytermin
peptid
remov
replac
gpi
anchor
addit
protein
gpi
apparantli
occur
intern
membran
detail
biosynthet
step
known
time
probabl
wide
use
valuabl
inhibitor
nlink
glycosyl
tunicamycin
compound
nucleosid
antibiot
produc
bacterium
streptomyc
lysosuperificu
initi
found
inhibit
replic
number
envelop
virus
structur
tunicamycin
elegantli
elucid
tamura
cowork
shown
fig
antibiot
contain
uracil
moieti
attach
nglycosid
bond
carbon
aminodeoxydialdos
call
tunicamin
tunicamin
substitut
glcnac
attach
structur
variou
tunicamycin
compon
r
refer
differ
ent
fatti
acid
design
x
may
attach
tunicamin
portion
molecul
anomer
carbon
oglycosid
bond
fatti
acid
link
amid
bond
amino
group
fatti
acid
may
vari
structur
c
c
may
satur
unsatur
may
branch
unbranch
fact
tunicamycin
actual
produc
complex
separ
mani
peak
hplc
basi
separ
fatti
acid
moieti
interestingli
enough
peak
biolog
activ
compo
nent
longer
chain
fatti
acid
appear
effect
inhibitor
cell
cultur
possibl
taken
cell
faster
rate
site
action
tunicamycin
initi
demonstr
microsom
enzym
prepar
calf
liver
antibiot
shown
potent
inhibitor
enzym
transfer
udpglcnac
dolichylp
reaction
produc
dolichylppglcnac
first
intermedi
dolichol
pathway
tunicamycin
site
action
plant
microsom
microsom
chick
oviduct
addit
tuni
camycin
potent
inhibitor
partial
purifi
prepar
udpglcnac
dolichylp
glcnaclp
transferas
sever
anim
tissu
inhibitor
also
affect
sever
microbi
enzym
involv
synthesi
peptidoglycan
ie
enzym
form
undecaprenylppivacetylmuramoylpentapeptid
enzym
involv
product
undecaprenylppglcnac
howev
tunicamycin
effect
glcnac
transferas
enzym
add
next
glcnac
dolichylppglcnac
enzym
add
termin
glcnac
residu
nlink
oligosaccharid
core
phosphotransferas
add
highmannos
chain
lysosom
enzym
tran
feras
add
glcnac
serin
residu
nuclear
protein
also
effect
format
undecaprenylppgalactos
undecaprenylppgalnac
high
concentr
inhibit
format
dolichylpglucos
sum
data
appear
tunicamycin
inhibit
phosphotransferas
catalyz
transloc
udp
deriv
polyprenylp
sugar
must
chiral
relat
glcnac
tunicamycin
probabl
competit
inhibitor
transferas
bind
tightli
enzym
possibl
revers
inhibit
ad
high
concentra
tion
udpglcnac
suggest
compound
tightbind
revers
inhibitor
might
substrateproduct
transitionst
analog
tunicamycin
use
mani
cell
cultur
system
tri
assess
role
nlink
glycosyl
function
variou
glycoprotein
probabl
best
test
whether
tunicamycin
realli
effect
prevent
glycosyl
cell
cultur
determin
whether
block
vivo
incorpor
label
glucosamin
dolichylppglcnac
incorpor
h
mannos
lipidlink
oligosaccharid
one
incub
cell
cultur
presenc
variou
concentr
tunicamycin
usual
min
hr
add
label
glucosamin
mannos
cell
appropri
period
label
deter
mine
experiment
cell
type
cell
pellet
extract
ch
h
ch
h
obtain
lipidlink
monosaccharid
lipidlink
oligo
saccharid
one
import
point
effect
concen
tration
inhibitor
may
vari
wide
depend
cell
system
use
optimum
concentr
need
determin
case
fact
demonstr
tunicamycinresist
mu
tant
isol
mutant
cell
amplifi
level
glcnaclp
transferas
thu
seem
reason
assum
level
enzym
therefor
suscept
cell
tunicamycin
may
vari
cell
cell
tissu
tissu
someth
els
consid
use
tunicamycin
function
studi
compound
may
inhibit
protein
synthesi
reason
effect
glycoprotein
function
thoroughli
examin
certain
result
absenc
carbohi
drate
rather
loss
certain
protein
exampl
variou
studi
tunicamycin
concentr
h
leucin
incorpor
protein
inhibit
glycosyl
inhibit
import
point
cell
type
much
sensit
inhibitor
cell
type
perhap
one
control
studi
would
use
inhibitor
ie
cycloheximid
puromycin
known
block
protein
synthesi
affect
carbohydr
synthesi
addit
inhibitor
mod
ifi
structur
carbohydr
chain
compar
effect
compound
tunicamycin
function
particular
glycoprotein
result
produc
glycoprotein
cell
presenc
tunicamycin
vari
consider
depend
glycoprotein
que
tion
term
structur
studi
tunicamycin
appropri
concentr
seem
prevent
glycosyl
nlink
glycopro
tein
regardless
biolog
system
howev
term
protein
portion
molecul
glycoprotein
still
synthes
normal
rate
still
secret
even
glycosyl
ate
thu
effect
inhibitor
secret
procolla
gen
chick
embryo
cell
secret
number
serum
protein
rat
hepatocyt
interferon
secret
leukocyt
l
cell
secret
enzym
fibroblast
observ
conclus
number
differ
type
cell
glycoprotein
requir
carbohi
drate
either
fold
conform
appear
function
normal
absenc
ad
carbohydr
protein
howev
greatli
affect
absenc
carbo
hydrat
thu
consider
decreas
rate
secret
ige
iga
mous
rat
plasma
cell
observ
presenc
tunicamycin
secret
igm
hybridoma
cell
one
rather
strang
interest
result
emerg
studi
observ
tunicamycin
inhibit
igm
secret
hybridoma
cell
affect
secret
igg
result
led
author
hypothes
differenti
effect
inhibi
tor
due
factor
intrins
respect
heavychain
polypep
tide
rather
properti
cell
would
seem
like
factor
relat
conform
respect
protein
influenc
carbohydr
protein
structur
andor
fold
surprisingli
tunicamycin
also
dramat
effect
membran
receptor
acetylcholin
receptor
muscl
cell
insulin
receptor
receptor
lowdens
lipoprotein
ldl
receptor
nerv
growth
factor
cite
exampl
gener
receptor
tunicamycin
significantli
decreas
number
receptor
molecul
cell
surfac
chang
total
number
receptor
cell
bind
affin
receptor
present
plasma
membran
studi
effect
tuni
camycin
revers
one
studi
insulin
receptor
appear
nonglycosyl
receptor
could
becom
glycosyl
remov
drug
would
suggest
case
protein
might
glycosyl
posttransl
sinc
preced
surfac
glycoprotein
endocytos
recycl
back
golgi
perhap
er
conceiv
glycosyl
could
occur
expos
asparagin
sequon
probabl
one
reason
great
variat
tunicamycin
effect
protein
function
glycoprotein
requir
link
oligosaccharid
stabil
longev
absenc
glycosyl
protein
rapidli
degrad
carbo
hydrat
may
protect
somehow
prevent
degrad
enzym
attack
glycosyl
protein
suggest
case
fibronectin
acetylcholin
receptor
influenza
viral
hemagglutinin
variou
immunoglobulin
cite
exampl
fact
influenza
system
observ
viral
replic
examin
presenc
tunicamycin
viral
envelop
glyco
protein
could
detect
howev
proteas
inhibitor
tcpk
leupeptin
ad
cell
along
tunicamycin
viral
protein
nonglycosyl
form
could
detect
studi
other
cite
indic
influenc
nlink
oligosaccharid
protein
question
depend
amino
acid
sequenc
turn
determin
fold
conform
thu
carbohydr
may
play
much
greater
role
affect
maintain
conform
protein
other
one
studi
provid
strong
support
hypothesi
amino
acid
sequenc
protein
determin
type
import
role
carbohydr
play
function
glycopro
tein
done
use
variou
temperaturesensit
mutant
vesicular
stomat
viru
vsv
grown
presenc
tunicamycin
one
strain
vsv
call
san
juan
strain
tunicamycin
prevent
viral
replic
viru
grown
either
howev
anoth
strain
call
orsay
strain
drug
inhibit
viral
replic
viru
grown
inhibit
furthermor
viru
grown
tunicamycin
nonglycosyl
viral
envelop
protein
g
protein
detect
host
cell
surfac
indic
synthes
target
normal
fashion
howev
protein
could
detect
cell
surfac
final
studi
physic
properti
variou
nonglycosyl
protein
also
indic
protein
differ
marked
solubl
deterg
triton
differ
temperatur
probabl
explana
tion
result
carbohydr
signific
role
provid
conform
increas
solubl
well
stabil
five
antibiot
describ
known
structur
function
relat
tunicamycin
antibiot
streptoviridin
mycospocidin
antibiot
antibiot
mm
corynetoxin
com
pound
gener
structur
tunicamycin
differ
natur
fatti
acid
attach
tunicamin
thu
case
may
ident
variou
tunicamycin
homolog
discuss
earlier
exampl
streptoviridin
compon
shorter
chain
fatti
acid
tunicamycin
evidenc
fact
molecular
weight
rang
wherea
tunicamycin
hand
hplc
comparison
mycospocidin
compon
tuni
camycin
complex
show
number
ident
compon
corynetoxin
interest
group
tunicamycinrel
com
pound
appear
involv
respons
ryegrass
toxic
case
develop
seed
head
annual
ryegrass
may
invad
nematod
caus
gall
produc
nematod
carri
bacterium
corynebacterium
rathayi
produc
tunicamycin
analog
corynetoxin
corynetoxin
apparantli
toxic
sheep
eat
infect
ryegrass
compound
appear
action
tuni
camycin
ie
inhibit
glcnaclp
transferas
detail
studi
mechan
action
done
streptoviridin
inhibitor
compar
tunicamycin
crude
partial
purifi
prepar
enzym
well
cell
cultur
system
indic
variou
tunicamycin
homolog
group
analog
also
show
differ
inhibitori
activ
compound
longer
chain
fatti
acid
effect
inhibitor
cell
cultur
system
shorter
chain
fatti
acid
addit
studi
cellfre
extract
partial
purifi
transferas
prepar
show
streptoviridin
lower
affin
enzym
tunicamycin
complex
fact
inhibitor
possibl
demonstr
competi
tive
inhibit
regard
udpglcnac
affin
glcnaclp
transferas
streptoviridin
consider
lower
tunicamycin
number
antibiot
compound
found
use
inhibitor
step
lipidlink
saccharid
pathway
mani
inhibitor
especi
antibiot
initi
discov
block
format
bacteri
cell
wall
polym
peptidoglycan
lipopolysaccharid
format
polym
also
involv
polyprenyllink
saccharid
intermedi
compound
appear
like
candid
test
nlink
glycosyl
pathway
exampl
antibiot
amphomycin
tsushimycin
inhibit
transferas
add
phosphonacetylmuramoylpentapeptid
grow
peptidoglycan
chain
wherea
bacitracin
inhibit
enzym
catalyz
dephosphoryl
undecaprenylpyrophosph
car
rier
lipid
cell
wall
biosynthesi
antibiot
also
inhibit
format
nlink
oligosaccharid
assembl
discuss
later
amphomycin
hydrophob
undecapeptid
contain
either
acid
attach
ntermin
aspart
acid
amid
linkag
structur
amphomycin
present
fig
cellfre
extract
aorta
tissu
amphomycin
block
format
dolichylpmannos
gdpmannos
affect
transfer
mannos
lipidlink
oligosaccharid
either
dolichylpmannos
gdpmannos
thu
microsom
incub
gdp
c
mannos
presenc
enough
amphomycin
complet
inhibit
format
dolichylp
c
mannos
extract
accumul
cman
glcnac
ppdolichol
abl
elong
lipid
larger
size
oligosaccharidelipid
hand
dolichylp
c
mannos
use
substrat
extract
mannos
transfer
oligosaccharidelipid
contain
six
mannos
residu
studi
suggest
first
five
mannos
residu
lipidlink
oligosaccharid
donat
gdpmannos
wherea
next
four
mannos
came
dolichylpmannos
similar
result
obtain
oviduct
tissu
embryon
liver
isol
cho
mutant
cell
line
miss
dolichylpmannos
synthas
clearli
establish
doli
chylpmannos
mannosyl
donor
last
four
mannos
residu
cellfre
extract
brain
tissu
amphomycin
inhibit
pro
duction
dolichylpglucos
dolichylpmannos
dolichylppglcnac
lead
investig
suggest
amphomycin
might
form
complex
dolichylp
dolichylp
deriv
evid
complex
dolichylp
amphomycin
obtain
although
clear
relat
inhibit
lipidlink
saccharid
format
amphomycin
also
use
variou
experi
one
studi
demonstr
dolichylp
involv
sugar
transloc
across
er
membran
one
case
show
dolichylpmannos
rather
gdpmannos
involv
elong
man
glcnac
ppdolichol
anoth
lipopeptid
antibiot
call
tsushimycin
mechan
action
similar
amphomycin
unfortu
nate
peptid
antibiot
appear
effect
cell
cultur
eucaryot
cell
probabl
cross
plasma
membran
bacitracin
anoth
lipopeptid
antibiot
use
studi
bacteri
cell
wall
biosynthesi
synthesi
lipidlink
saccharid
structur
compound
present
fig
bacitracin
shown
inhibit
synthesi
bacteri
cell
wall
peptidoglycan
inhibit
dephosphoryl
undecaprenylpyrophosph
necessari
reutil
carrier
molecul
anim
cell
specif
site
inhibit
antibiot
clear
report
act
sever
differ
point
includ
mannosyltransferas
add
mannos
trisaccharidelipid
glcnac
ppdolichol
transferas
form
glcnacppdolichol
glcnac
transferas
form
glcnacglcnacppdolichol
seem
like
action
inhibitor
similar
ampho
mycin
ie
may
bind
variou
dolichyl
deriv
right
condit
therefor
may
interfer
varieti
reaction
dolichol
cycl
sever
antibiot
affect
synthesi
bacteri
cell
wall
also
effect
reaction
describ
gener
compound
well
defin
structur
function
inhibitori
action
report
structur
diumycin
known
report
inhibit
format
dolichylpmannos
yeast
membran
prepar
well
transfer
mannos
dolichylpmannos
serin
threonin
residu
membran
prepar
acanthamoeba
diu
mycin
block
transfer
mannos
glcnac
lipidlink
monosaccharid
affect
synthesi
dolichylpglucos
fact
diumycin
anoth
antibiot
showdomycin
use
add
support
hypothesi
dolichylpmannos
posit
regul
transferas
form
glcnacppdolichol
thu
either
drug
ad
microsom
prepar
block
format
dolichylpmannos
gdpmannos
therefor
prevent
stimul
glcnacppdolichol
format
gdpmannos
flavomycin
antibiot
moenomycin
group
compound
drug
interfer
format
lipidlink
saccharid
microsom
pig
brain
unfortun
studi
report
compound
addit
studi
need
understand
mechan
action
appli
diumycin
showdomycin
nucleosid
antibiot
whose
structur
shown
fig
compound
maleimid
group
react
sulfhydryl
protein
reaction
probabl
basi
show
domycin
inhibit
lipidlink
saccharid
format
cellfre
extract
aorta
synthesi
dolichylpmannos
dolichylpglucos
inhibit
drug
format
dolichylppglcnac
affect
howev
volvox
extract
synthes
dolichylpglucos
dolichylppglcnac
equal
sensit
showdomycin
presenc
triton
inhibit
revers
addit
dithiothreitol
indic
earlier
showdomycin
also
use
studi
regul
lipidlink
saccharid
format
dolichylpmannos
probabl
two
earliest
inhibitor
viral
envelop
format
describ
glucosamin
known
glucosamin
interfer
format
lipidlink
oligosaccharid
block
protein
glycosyl
inhibi
tion
howev
requir
intact
cell
involv
metabol
glucosamin
probabl
intermedi
udpglucosamin
may
compet
udpglcnac
variou
glcnac
transferas
mdck
cell
incub
presenc
mm
glucosamin
complet
shift
composit
lipidlink
oligosaccharid
mostli
glc
man
glcnac
ppdolichol
normal
cell
man
glcnac
ppdolichol
inhibit
cell
shift
smaller
size
oligosaccharidelipid
becam
even
pronounc
concentr
glucosamin
rais
mm
glucosamin
effect
could
revers
remov
aminosugar
cultur
medium
exact
site
mechan
action
compound
still
unknown
interestingli
enough
anoth
aminosugar
mannosamin
also
hibit
format
lipidlink
oligosaccharid
mecha
nism
action
compound
quit
differ
gluco
amin
inhibit
mannosamin
dosedepend
result
shift
size
oligosaccharid
moieti
lipidlink
oligosaccharid
glc
man
glcnac
ppdolichol
lipid
man
glcnac
man
glcnac
major
speci
oligosaccharid
five
six
mannos
residu
studi
demonstr
mannosamin
incorpor
lipidlink
oligosaccharid
mostli
place
mannos
mannos
substitut
appear
prevent
addit
mannos
mannosam
ine
presenc
mannosamin
seri
basic
oligosaccha
ride
link
dolichol
form
least
oligosac
charid
still
transfer
protein
howev
clear
whether
alter
glycopeptid
process
normal
pathway
accumul
cell
mannosamin
mannos
contain
structur
term
glucos
analog
clear
sugar
metabol
cell
convert
well
inhibit
glycoprotein
synthesi
deoxysugar
appear
due
glucos
mannos
revers
inhibit
probabl
deoxyglucos
incorpor
lipidlink
oligosaccharid
instead
mannos
act
like
mannosamin
prevent
extens
chain
addit
mannos
link
oligosaccharid
ap
pear
transfer
protein
contrast
situat
mannosaminecontain
oligosaccharid
lipidlink
oligosaccharid
number
fluorosugar
also
shown
inhibitor
glycosyl
seem
like
mechan
action
analog
similar
anim
cell
especi
chines
hamster
ovari
cho
cell
show
phenomenon
call
glucos
starvat
thu
glucos
remov
medium
cell
longer
produc
typic
glc
man
glcnac
ppdolichol
natur
oligosaccharid
donor
nlink
glycosyl
instead
cell
produc
truncat
lipidlink
oligosaccharid
man
glcnac
ppdolichol
ie
glucosyl
intermedi
produc
glc
man
glcnac
ppdolichol
appear
glucos
starvat
condit
cell
abl
synthes
dolichylpmannos
reason
lesion
clear
cell
still
make
dolichylpglucos
appear
glucosyl
oligosaccharid
sever
cell
line
effect
glucos
starva
tion
seen
within
min
remov
glucos
long
cell
low
moder
densiti
high
densiti
effect
seen
glucos
starvat
phenomenon
could
overcom
addit
glucos
addit
galactos
glutamin
pyruv
inositol
glycerol
rat
hepatoma
cell
starv
glucos
lower
molecular
weight
form
r
acid
glycoprotein
produc
decreas
molecular
weight
due
truncat
oligosaccharid
also
fewer
oligosaccharid
chain
protein
carbonylcyanid
mchlorophenylhydrazon
cccp
uncoupl
oxid
phosphoryl
caus
cell
deplet
energi
compound
given
variou
anim
cell
caus
similar
situat
seen
glucos
starvart
ie
cell
unabl
produc
dolichylpmannos
although
still
synthes
dolichylppglcnac
dolichylpglucos
cell
form
glc
man
glcnac
ppdolichol
transfer
oligosaccharid
protein
hand
thyroid
slice
incub
cccp
man
glcnac
ppdolichol
intermedi
produc
decreas
nlink
glycosyl
observ
studi
inhibi
tor
respir
n
antimycin
caus
effect
sinc
uncoupl
oxid
phosphoryl
report
disrupt
recycl
glucos
transport
compound
may
limit
entri
glucos
cell
thu
mimick
glucos
starvat
effect
puzzl
mention
earlier
ie
format
dolichylpmannos
inhibit
dolichylpglucos
perhap
could
someth
postul
dolichylpmannos
synthas
regulatori
en
zyme
protein
undergo
phosphoryl
condit
number
natur
occur
sugarlik
compound
ring
oxygen
replac
nitrogen
isol
alkaloid
found
potent
inhibitor
variou
glycosidas
apparantli
nitrogen
ring
make
compound
inact
metabol
standpoint
still
recogn
specif
glycosidas
therefor
function
use
enzym
inhibitor
enzym
involv
earli
glycoprotein
process
reaction
glycosidas
inhibitor
play
signific
role
studi
sequenc
reaction
nlink
oligosaccharid
well
requir
glycoprotein
process
mani
anim
cell
line
mani
inhibitor
isol
plant
sourc
character
structur
demonstra
tion
biolog
activ
stimul
chemic
synthesi
number
analogu
plant
inhibitor
alkaloid
fall
variou
chemic
class
design
piperidin
pyrroli
dine
indolizidin
pyrrolizidin
castanospermin
indolizidin
alkaloid
found
seed
australian
chestnut
tree
castanospermum
austral
structur
shown
fig
alkaloid
potent
inhibitor
also
inhibit
glycoprotein
process
glucosidas
ii
well
variou
sucras
maltas
lysosom
aglucosidas
compound
structur
variou
glucosidas
inhibitor
castanospermin
inhibitor
glucosidas
glucosi
dase
ii
wherea
australin
much
better
inhibitor
glucosidas
glucosidas
ii
mdl
potent
inhibitor
glucosidas
ii
lentiginosin
shown
compari
son
inhibitor
amyloglucosidas
ineffect
process
glucosidas
strong
inhibitor
sucras
maltas
therefor
prevent
normal
digest
starch
sucros
seed
plant
toxic
anim
caus
sever
diarrhea
variou
cultur
anim
cell
grown
incub
presenc
alkaloid
process
nlink
glycoprotein
block
first
step
pathway
see
fig
asparaginelink
glycoprotein
oligosaccharid
mostli
glc
man
glcnac
structur
anoth
glucosidas
inhibitor
polyhydroxyl
piperidin
analog
nojirimycin
correspond
glucos
pyranos
ring
form
see
fig
compound
origin
isol
streptomyc
found
potent
inhibitor
aand
chemic
reduct
nojirimycin
gave
stabl
deoxynojirimycin
also
glucosidas
inhibitor
subsequ
isol
bacteria
plant
deoxynojirimycin
caus
gener
effect
cell
cultur
castanospermin
although
activ
toward
glucosidas
ii
toward
glucosidas
caus
alter
chang
structur
lipidlink
saccharid
anoth
glucosidas
inhibitor
also
found
plant
pyrrolidin
alkaloid
compound
although
consider
less
effect
sixmemb
ring
structur
describ
eg
compar
structur
fig
castanospermin
deoxynojirimycin
caus
similar
chang
structur
nlink
oligosaccharid
effect
glycoprotein
target
function
prevent
remov
glucos
nlink
oligosaccharid
quit
dra
matic
exampl
hepatocyt
cell
incub
presenc
deoxynojirimycin
rate
secret
r
antitrypsin
substanti
diminish
wherea
rate
secret
nlink
glycoprotein
ceruloplasmin
compon
complement
margin
alter
base
preliminari
cell
fraction
studi
suggest
presenc
glucos
oligosaccharid
certain
glycoprotein
might
retard
move
ment
glycoprotein
er
golgi
apparatu
similar
result
obtain
fibroblast
smooth
muscl
cell
effect
castanospermin
ldl
receptor
examin
case
signific
decreas
bind
endocytosi
ldl
arteri
smooth
muscl
cell
upregul
produc
ldl
receptor
presenc
castanospermin
reason
decreas
bind
shown
due
reduc
number
receptor
cell
surfac
rather
chang
affin
receptor
ligand
furthermor
total
number
ldl
recep
tor
cell
chang
presenc
castanospermin
indic
drug
inhibit
synthesi
receptor
affect
degrad
cell
fraction
studi
design
isol
variou
membran
fraction
demonstr
shift
distri
bution
ldl
receptor
within
cell
compart
indic
decreas
receptor
cell
surfac
correspond
increas
receptor
ergolgi
membran
fraction
case
lymphocyt
castanospermin
use
studi
biosynthesi
process
insulin
receptor
cell
treat
alkaloid
show
decreas
cellsurfac
insulin
receptor
demonstr
bind
iinsulin
well
na
ilactoperoxidas
label
crosslink
studi
iinsulin
studi
demonstr
pro
cess
ie
remov
glucos
nlink
oligosaccharid
necessari
cleavag
insulin
proreceptor
ie
protein
matur
howev
indic
presenc
glu
cose
appear
slow
transport
glycoprotein
er
golgi
apparatu
data
suggest
presenc
glucos
receptor
er
hold
bind
glucosecontain
glycoprotein
data
may
indic
protein
undergo
conform
chang
glucos
remov
newli
alter
protein
transfer
er
golgi
rapid
rate
case
synthesi
e
glycoprotein
coronaviru
casta
nospermin
deoxynojirimycin
caus
drop
viru
format
log
also
caus
dramat
decreas
appear
e
cell
surfac
interestingli
enough
e
produc
presenc
drug
still
acyl
fatti
acid
control
e
glycoprotein
accumul
intracellularli
compart
distinct
golgi
apparatu
could
compart
er
anoth
case
posttransl
addit
palmit
acid
also
affect
glucosidas
inhibitor
na
channel
rat
brain
neuron
compos
aand
form
complex
matur
posttransl
modifi
addi
tion
palmit
acid
incorpor
label
palmit
glycoprotein
block
glycosyl
inhibitor
tunicamycin
howev
form
presenc
castanospermin
lower
molecular
weight
contain
sialic
acid
lower
sulfat
content
similar
control
content
palmit
acid
drug
also
prevent
coval
assembl
aand
affect
biolog
activ
channel
regard
bind
saxitoxin
extern
glycoprotein
aidsassoci
viru
hiv
call
heavili
glycosyl
protein
involv
mechan
attach
hiv
receptor
lymphocyt
suscept
cell
interact
target
molecul
suscept
cell
caus
fusion
cell
refer
format
syncytia
glucosidas
inhibitor
ie
castanospsermin
deoxynojirimycin
caus
drastic
inhibit
viru
replic
well
syncytium
format
interest
result
castanospermin
deoxynojirimycin
well
glucosidas
ii
inhibitor
analog
variou
inhibitor
test
potenti
antiaid
compound
shown
fig
compound
besid
castano
spermin
deoxynojirimycin
also
activ
function
glycoprotein
process
inhibitor
one
compound
pyrrolidin
alkaloid
mention
earlier
refer
dmdp
found
sever
plant
leguminosa
famili
cell
cultur
dmdp
give
type
oligosaccharid
structur
ie
glc
man
glcnac
castanospermin
although
much
less
activ
inhibitor
ie
higher
concentr
requir
nevertheless
interest
inhibitor
demonstr
sixmemb
ring
structur
absolut
requir
inhibitori
activ
knowledg
structur
help
us
defin
particular
structur
requir
necessari
biolog
activ
along
line
two
structur
also
interest
glucosidas
inhibitor
partli
unusu
partli
show
select
describ
thu
far
shown
fig
australin
tetrahydroxypyrrolizidin
alkaloid
isol
seed
tree
c
austral
castanospermin
compound
uniqu
substitut
pattern
ie
bicycl
alkaloid
reason
good
competit
inhibitor
fungal
amyloglucosidas
arylglucosidas
also
inhibit
glycoprotein
pro
cess
enzym
glucosidas
howev
contrast
castanospermin
deoxynojirimycin
australin
poor
inhibitor
glucosidas
ii
compound
first
glucosidas
inhibitor
distinguish
two
process
glucosidas
thu
addit
compound
australin
show
increas
specif
valuabl
help
us
understand
two
glucosidas
differ
mecha
nism
catalysi
also
determin
chiral
spacial
config
urat
necessari
activ
variou
glycosidas
anoth
inhibitor
whose
structur
shown
fig
dglucopyranosyl
dglycerolguloheptitol
mdl
compound
chemic
synthes
mimic
disaccharid
would
act
transit
state
analog
intestin
enzym
sucras
anticip
mdl
inhibit
rat
intestin
maltas
sucras
isomaltas
glucoamylas
trehalas
micromolar
con
centrat
interestingli
enough
test
glycoprotein
pro
cess
glucosidas
opposit
australin
specif
mdl
much
effect
inhibitor
glucosidas
ii
glucosidas
cell
cultur
experi
mdl
caus
accumul
glycoprotein
mostli
glc
man
glcnac
structur
find
australin
mdl
specif
inhibitor
castanospermin
deoxynojirimycin
hope
stimul
intens
search
natur
occur
inhibitor
improv
select
glucosidas
mannosidas
also
entic
chemist
use
imagin
synthes
novel
compound
first
glycoprotein
process
inhibitor
report
swainsonin
describ
detail
indolizidin
alkaloid
initi
found
inhibitor
lysosom
arylmannosidas
later
shown
specif
inhibit
process
mannosidas
ii
howev
eas
understand
consid
variou
mannosidas
inhibitor
order
occur
process
pathway
rather
order
first
report
discoveri
deoxynojirimycin
castanospermin
glycopro
tein
process
inhibitor
indic
good
glycosidas
inhibitor
possess
follow
properti
pyranos
ring
structur
nitrogen
ring
replac
oxygen
b
stereochem
istri
hydroxyl
group
keep
particular
sugar
recogn
glycosidas
interest
thu
reason
assum
structur
similar
deoxynojirimycin
mannos
configur
ie
good
inhibitor
mannosidas
deoxynojirimycin
syn
thesiz
chemic
inde
found
potent
inhibitor
glycoprotein
process
enzym
mannosidas
surprisingli
enough
deoxymannojirimycin
inhibit
jack
bean
lysosom
inhibit
che
process
mannosidas
ii
fact
inhibitor
demonstr
thai
danger
screen
new
inhibitor
use
arylglycosidas
sourc
enzym
even
use
process
enzym
use
desir
process
inhibitor
specif
particular
process
glycosidas
may
inhibit
activ
structur
deoxymannojirimycin
swainsonin
known
mannosidas
inhibitor
shown
fig
sinc
time
mani
studi
deoxymannojirimycin
done
sever
neutral
differ
specif
enzym
distinct
mannosidas
mannosidas
ii
identifi
enzym
found
resist
inhibit
deoxymannojirimycin
enough
mannosi
dase
inhibitor
yet
known
abl
specif
inhibit
activ
addit
enzym
yet
purifi
test
variou
process
inhibitor
anim
cell
deoxymannojirimycin
inhibit
golgi
mannosidas
iab
caus
accumul
glycoprotein
hav
ing
highmannos
oligosaccharid
mostli
man
glcnac
structur
inhibitor
howev
prevent
secret
igd
igm
cell
cultur
although
glucos
analog
deoxynojiri
mycin
thu
presenc
glucos
oligosaccharid
signific
effect
intracellular
transport
least
glycoprotein
presenc
highmannos
oligosaccharid
rather
normal
complex
chain
appear
problem
term
protein
secret
deoxymannojirimycin
also
without
effect
format
appear
g
protein
vesicular
stomat
viru
hemagglutinin
influenza
viru
hla
b
c
antigen
well
r
aeid
glycoprotein
r
proteas
inhibitor
deoxymannojirimycin
use
one
studi
determin
mem
brane
glycoprotein
recycl
golgi
apparatu
endocyt
process
experi
membran
glycoprotein
synthes
label
h
mannos
presenc
deoxymannojirimycin
glycoprotein
would
highmannos
structur
inhibitor
label
sugar
move
oligosaccharid
structur
transferrin
receptor
determin
variou
time
condit
receptor
would
endocytos
initi
oligosaccharid
tran
ferrin
receptor
highmannos
structur
presenc
deoxymannojirimycin
synthesi
chase
small
percentag
recycl
receptor
underw
process
attain
complex
type
oligosaccharid
structur
indic
endocytos
glycoprotein
recycl
cisgolgi
compart
howev
amount
glycoprotein
actual
underw
modif
recycl
quit
small
indic
glycoprotein
recycl
golgi
probabl
major
rout
role
endoplasm
reticulum
also
examin
cell
cell
line
overexpress
hmg
coa
reductas
hmg
coa
reductas
resid
er
cell
glycoprotein
high
mannos
oligosaccharid
mostli
man
glcnac
man
glcnac
structur
previou
studi
indic
er
inhibit
deoxymannojirimycin
thu
presenc
deoxymannojirimycin
initi
trim
oligo
saccharid
chain
reductas
still
occur
case
major
oligosaccharid
structur
protein
man
glcnac
smaller
size
oligosaccharid
detect
studi
indic
er
involv
remov
first
mannos
necessari
remov
mannos
residu
anoth
mannosidas
inhibitor
dim
inhibitor
furanos
ring
structur
rather
pyranos
ring
inhibitor
dim
synthes
chemic
benzyladmannopyranos
found
good
inhibitor
jack
bean
also
inhibit
pro
cess
nlink
glycoprotein
cell
cultur
ad
cultur
medium
mdck
cell
experi
major
oligosaccharid
form
cell
glycoprotein
man
glcnac
structur
keep
hypothesi
dim
inhibit
golgi
mannosidas
howev
known
whether
dim
also
inhib
er
mannosidas
activ
appear
present
mdck
cell
furthermor
indic
inhibitor
test
er
mannosidas
mannosidas
although
activ
mannosidas
thu
vitro
stud
i
dim
partial
purifi
prepar
mannosidas
rat
liver
show
compound
inhibit
releas
h
mannos
h
mannoselabel
man
glcnac
dim
nearli
effect
mannosidas
inhibitor
swainsonin
kifunensin
howev
much
readili
avail
larg
amount
chemic
synthesi
quit
simpl
therefor
dim
isom
valuabl
anim
studi
well
experi
requir
larg
amount
mannosidas
inhibitor
kifunensin
alkaloid
produc
actinomycet
kitasatosporia
kifunens
correspond
structur
cyclic
oxamid
deriv
kifunensin
weak
inhibitor
jack
bean
ic
potent
inhibitor
glycoprotein
process
mannosidas
ic
thu
inhibitor
time
effect
enzym
deoxymannojirimycin
hand
kifunensin
effect
mannosidas
use
rat
liver
microsom
sourc
mannosidas
activ
kifunensin
strongli
inhibit
golgi
mannosidas
probabl
without
effect
propos
er
cell
cultur
mdck
cell
kifunensin
gave
rise
glycoprotein
man
glcnac
structur
deoxymannojirimycin
amount
kifunen
sine
need
effect
onefiftieth
much
deoxi
mannojirimycin
recent
broadspectrum
inhibitor
synthes
chemic
mimic
mannopyranosyl
cation
put
intermedi
hydrolysi
mannopyranosid
compound
whose
structur
shown
fig
call
mannonolactam
amidrazon
compound
found
gener
mannosidas
inhibitor
current
known
com
pound
shown
fig
thu
amidrazon
inhibit
golgi
mannosidas
ic
mannosidas
ii
ic
nm
also
first
compound
found
potent
inhibitor
solubl
er
ic
addit
amidrazon
also
inhibit
arylamannosidas
although
much
effect
enzym
recogn
ic
jack
bean
compar
mannosidas
cell
cultur
studi
amidrazon
complet
prevent
forma
tion
complex
type
oligosaccharid
instead
caus
forma
tion
oligosaccharid
man
glcnac
man
glcnac
structur
hypothes
reason
compound
effect
mannosidas
first
monosaccharid
analog
mimic
true
halfchair
conform
cation
intermedi
believ
involv
catali
si
glycosid
bond
compound
serv
use
model
synthes
specif
mannosidas
inhibitor
indic
first
glycoprotein
process
inhibitor
identifi
swainsonin
initi
interest
compound
due
fact
found
plant
toxic
graze
anim
australia
major
plant
alkaloid
call
swainsona
canescen
unit
state
variou
plant
genu
astragalu
contain
swainsonin
plant
present
major
hazard
livestock
industri
caus
sever
neurolog
skelet
problem
anim
feed
earli
studi
inhibit
arylamannosidas
swainsonin
sug
gest
potent
inhibitori
activ
ic
result
structur
similar
proton
form
swainsonin
mannosyl
cation
sinc
glycosyl
ion
intermedi
probabl
form
natur
hydrolysi
glycosidas
lymphnod
sheep
injest
toxic
plant
contain
high
level
mannoserich
oligosaccharid
led
postul
swainsonin
caus
lysosomallik
storag
diseas
similar
human
morpholog
biochem
swainsonin
actual
caus
agent
symptom
indic
feed
pig
either
whole
toxic
plant
ie
astragalu
swainsonin
show
set
anim
exhibit
symptom
anim
liver
golgi
mannosidas
ii
activ
significantli
decreas
strang
enough
number
lysosom
hydrolas
amannosidas
hexosaminidas
increas
activ
iti
addit
activ
variou
hydrolas
plasma
also
elev
sheep
fed
locowe
variou
highmannos
oligosaccharid
found
urin
two
major
oligosaccharid
identi
fie
man
glcnac
man
glcnac
rel
abun
danc
variou
oligosaccharid
chang
cours
feed
feed
discontinu
amount
urinari
oligosaccharid
declin
rapidli
reach
baselin
within
day
similar
type
highmannos
oligosaccharid
also
accumu
late
rat
guinea
pig
fed
swainsonin
differ
structur
especi
presenc
one
two
glcnac
residu
near
reduc
terminu
differ
enc
probabl
reflect
presenc
absenc
endoglucosaminidas
anim
swainsonin
first
compound
shown
inhibit
glyco
protein
process
initi
studi
swainsonin
ad
cultur
medium
mdck
cell
found
caus
great
decreas
amount
h
mannos
incorport
complex
type
glycoprotein
correspond
increas
incorpor
label
sugar
oligosaccharid
sensit
digest
endoglucosaminidas
h
influenzavirusinfect
mdck
cell
swainsonin
caus
viral
hemagglutinin
nlink
glycoprotein
sever
complex
chain
migrat
rapidli
sd
gel
chang
shown
due
chang
structur
nlink
oligosaccharid
later
studi
purifi
process
enzym
show
site
action
swainsonin
golgi
mannosidas
ii
alkaloid
inact
toward
pro
cess
mannosidas
keep
site
action
indolizidin
alkaloid
also
caus
format
hybrid
type
struc
ture
place
cultur
medium
cell
produc
variou
glycoprotein
vsv
g
protein
fibronectin
bhk
cell
surfac
glycoprotein
swainsonin
use
number
cell
cultur
system
tri
determin
role
specif
oligosaccharid
structur
glycoprotein
function
studi
swainsonin
found
littl
effect
glycoprotein
question
indic
partial
complex
oligosac
charid
ie
hybrid
chain
suffici
function
activ
least
tissu
cultur
exampl
swainsonin
impair
synthesi
export
thyroglobulin
porcin
thyroid
cell
affect
surfact
glycoprotein
type
ii
epitheli
cell
histocompat
antigen
macrophag
von
willebrand
protein
epitheli
cell
also
affect
target
function
variou
membran
receptor
includ
insulin
receptor
epiderm
growth
factor
receptor
receptor
asialoglycoprotein
inhibitor
howev
block
receptormedi
uptak
mannosetermin
glycoprotein
macro
phage
blockag
appear
due
format
hybrid
type
glycoprotein
macrophag
surfac
react
bound
mannos
receptor
swainsonin
prove
use
demonstr
sequenc
addit
variou
sugar
nlink
oligosaccharid
assembl
pathway
thu
fucosyl
sulfat
influenza
viral
hemaggluti
nin
examin
cell
grown
presenc
swainsonin
castanospermin
found
hemagglutinin
contain
h
fucos
sulfat
viru
rais
presenc
swainsonin
viru
produc
presenc
castanospermin
deoxymannojirimycin
studi
suggest
fucosyltransferas
sulfotransferas
recogn
glcnacman
glcnac
structur
appropri
acceptor
sub
strate
protein
show
loss
function
produc
presenc
swainsonin
thu
glucocorticoid
stimul
resorpt
cell
appear
involv
attach
osteoblast
relat
cell
bone
inhibit
block
swainsonin
drug
also
reduc
interact
tyrpanosoma
cruzi
peri
toneal
macrophag
either
host
cell
parasit
treat
swainsonin
also
dramat
declin
abil
melanoma
cell
colon
lung
experiment
anim
observ
cell
incub
swainsonin
treatment
lymphocyt
mitogen
concanavalin
stimul
prolifer
prolifer
block
immunosuppres
factor
found
serum
mice
contain
tumor
sarcoma
suppress
caus
factor
somehow
come
swainsonin
indic
alkaloid
might
chemotherapeut
valu
immunosuppress
diseas
turnov
degrad
endocytos
glycoprotein
also
inhibit
swainsonin
lead
accumul
glycopro
tein
lysosom
tissu
cultur
cell
incub
drug
block
appear
due
inhibit
lysosom
mannosi
dase
perhap
enzym
indic
carbohydr
portion
glycoprotein
must
degrad
protein
studi
suggest
swainsonin
may
import
effect
cell
system
therefor
relat
compound
may
chemotherapeut
valu
howev
addit
studi
requir
inhibitor
anoth
inhibitor
mannosidas
ii
recent
isol
fungu
call
mannostatin
compound
interest
one
inhibitor
present
known
exocycl
nitrogen
rather
nitrogen
ring
addit
seen
fig
mannostatin
thiomethyl
group
fivememb
ring
mannostatin
found
potent
inhibitor
mannosidas
ii
ic
nm
jack
bean
mannosidas
cell
cultur
studi
mannostatin
gave
rise
type
hybrid
structur
observ
cell
incub
presenc
swasinsonin
howev
nacetyl
deriv
mannostatin
inact
mannosidas
although
mannostatin
differ
site
action
activ
swain
sonin
interest
addit
repertoir
inhibitor
caus
show
heretofor
unanticip
structur
glycosidas
inhibitor
open
number
new
possibl
chemic
synthesi
relat
structur
perhap
structur
combin
aspect
mannostatin
aspect
alkaloid
number
laboratori
develop
method
syn
thesi
alkaloid
deriv
well
new
inhibitor
far
except
mannostatin
inhibitor
nitrogen
ring
place
oxygen
least
three
assi
metric
hydroxi
group
substitut
ring
oxygen
nitrogen
apparantli
render
compound
metabol
inert
prevent
recognit
compound
glycosidas
perhap
carbohydr
recogn
enzym
presum
hydroxyl
group
inhibitor
chiral
sugar
substrat
glycosidas
inhibit
interestingli
enough
inhibitor
necessarili
need
sixmemb
ring
structur
mimic
catalyt
intermedi
involv
substrat
recognit
hydrolyt
step
fact
swainsonin
best
fit
mannos
analog
stagger
halfchair
conform
pyrrolidin
pyrrolizidin
ring
structur
may
also
assum
similar
conform
molecular
model
studi
compound
help
stand
mechan
inhibit
compound
model
studi
done
mannosidas
inhibi
tor
compar
mannopyranosyl
cation
activ
intermedi
ate
jack
bean
mannosidas
howev
synthesi
isol
differ
inhibitor
enzym
add
infor
mation
synthesi
lipidlink
oligosaccharid
anim
tissu
cultur
anim
cell
shown
inhibit
sever
inhibitor
protein
synthesi
exampl
mdck
cell
grown
presenc
cycloheximid
puromycin
hibitor
protein
synthesi
differ
mechan
dosedepend
inhibit
incorpor
h
mannos
lipidlink
oligosaccharid
howev
inhibitor
affect
mannos
incorpor
dolichylpmannos
block
mannos
incorpor
gdp
c
mannos
lipidlink
saccharid
cellfre
extract
prepar
mdck
cell
porcin
aorta
result
could
explain
one
follow
postul
limit
amount
dolichylp
avail
serv
carrier
sugar
b
feedback
inhibit
synthesi
lipidlink
saccharid
caus
accumul
lipidlink
oligosaccharid
result
lack
acceptor
protein
howev
sinc
synthesi
dolichylpmannos
inhibit
feedback
mechan
seem
like
addit
studi
show
inhibit
cycloheximid
could
overcom
ad
exogen
dolichylp
even
though
addit
dolichylp
normal
cell
stimul
incorpor
mannos
lipidlink
saccharid
howev
specif
site
inhibit
feedback
inhibit
inhibitor
known
actinomycin
inhibitor
rna
synthesi
also
found
inhibit
incorpora
tion
mannos
lipidlink
oligosaccharid
exact
site
inhibit
determin
base
result
well
addit
studi
level
variou
intermedi
normal
inhibit
cell
postul
mechan
inhibit
involv
feedback
type
control
caus
ele
vate
level
gtp
cell
nlink
glycosyl
consensu
sequenc
accept
oligosaccharid
chain
h
n
asnxser
thr
x
amino
acid
except
prolin
aspart
acid
sequenc
howev
suffici
glycosyl
occur
conforma
tion
protein
around
glycosyl
site
apparantli
also
critic
statist
studi
number
asparaginelink
glycopro
tein
indic
asparagin
residu
come
glycosyl
locat
region
polypeptid
chain
favor
format
import
threonin
residu
tripeptid
sequenc
examin
use
threonin
analog
determin
effect
cotransl
glycosyl
extract
ascit
cell
analog
inhibit
glycosyl
human
chorion
gonadotropin
subunit
bovin
leutin
hormon
inhibit
could
overcom
ad
threonin
strongli
suggest
analog
inhibit
compet
threonin
incorpor
protein
cultur
fibroblast
caus
format
varieti
cathepsin
molecul
differ
one
two
oligosaccharid
chain
protein
nonglycosyl
form
cathepsin
minor
compon
rapidli
degrad
within
min
synthesi
howev
form
one
two
oligosaccharid
chain
behav
normal
segreg
lysosom
underw
proteolyt
matur
usual
fashion
simi
lar
type
result
observ
respect
effect
analog
format
r
acid
glycoprotein
anoth
amino
acid
analog
interest
effect
glycosyla
tion
analog
toxic
asparaginedepend
cell
aspart
acid
includ
cultur
medium
actual
mechan
toxic
determin
believ
due
incorpor
analog
protein
mm
concentr
analog
strongli
inhibit
glycosyl
inhibit
block
ad
asparagin
strengthen
idea
analog
incorpor
howev
erythroanalog
inhibitor
glycosyl
interestingli
enough
two
amino
acid
analog
ie
use
inhibit
protein
synthesi
also
inhibit
incorpor
radioact
mannos
lipidlink
oligosaccharid
demonstr
cycloheximid
puromycin
seem
like
toxic
fluoroasparagin
due
prevent
cell
glycosyl
nlink
glycoprotein
much
manner
tunicamycin
vii
indic
earlier
dolichylp
serv
obligatori
carrier
glycosyl
nlink
glycoprotein
dolichylp
produc
initi
pathway
respons
synthesi
polyprenol
unit
therefor
one
would
anticip
inhibitor
polyprenol
format
also
inhibit
dolichylp
format
fur
thermor
inhibitor
also
potent
effect
gli
cosyl
asparaginelink
glycoprotein
sinc
format
polyphenol
util
ratelimit
step
catalyz
enzym
hydroxymethylglutarylco
reductas
hmg
coa
reductas
inhibi
tor
enzym
compactin
mevanolin
also
inhibit
glycosyl
smooth
muscl
cell
deriv
aorta
grown
presenc
incorpor
c
acet
cholesterol
dolichylp
inhibit
nlink
glycosyl
howev
mevalon
incorpor
lipid
unaffect
expect
mevalon
fact
ad
inhibit
cell
overcom
inhibit
respect
nlink
glycosyl
presum
allow
dolichylp
form
hand
mous
l
cell
hydroxycholesterol
also
affect
synthesi
dolichol
cholesterol
system
condit
gave
great
fluctuat
cholesterol
synthesi
slight
effect
dolichylp
format
author
postul
point
pathway
must
control
level
two
lipid
ie
cholesterol
dolichol
cholestyraminei
compound
fed
anim
caus
increas
activ
hmg
coa
reductas
great
stimul
incorpor
acet
cholesterol
howev
increas
incorpor
acet
dolichylp
hand
feed
anim
diet
high
cholesterol
would
expect
suppress
cholesterol
synthesi
level
hmg
coa
reductas
howev
treatment
caus
signific
increas
incorpor
mevalon
dolichol
dolichollink
oligosaccharid
well
increas
activ
glycosyltransferas
requir
glycoprotein
synthesi
explan
data
clear
perhap
inhibit
cholesterol
branch
polyprenol
pathway
result
accumula
tion
certain
intermedi
key
player
branch
biosynthet
pathway
compactin
fungal
product
competit
inhibitor
hmg
coa
reductas
compactin
number
chemic
synth
size
deriv
structur
ie
mevinolin
studi
extens
enorm
chemotherapeut
potenti
lower
serum
cholesterol
level
one
studi
rat
hepatocyt
cultur
compactin
hr
synthesi
dolichylp
decreas
suggest
dolichylp
mainli
synth
size
de
novo
pathway
ctpmediat
phosphoryla
tion
dolichol
limit
use
howev
anoth
studi
indi
cate
dolichol
kinas
dolichylp
phosphatas
play
key
role
regul
cellular
level
dolichylp
com
pactin
concentr
fed
sea
urchin
embryo
induc
abnorm
gastrul
effect
appear
due
inhibit
dolichylp
format
embryo
also
show
decreas
capac
synthes
lipidlink
oligosaccharid
glycoprotein
furthermor
inhibitori
effect
compactin
devel
opment
could
overcom
supplement
embryo
dolichylp
addit
cholesterol
coenzym
q
could
overcom
inhibit
similar
result
obtain
mous
embryo
compactin
oxygen
sterol
arrest
develop
stage
left
blastomer
decompact
also
nglycosyl
effect
affect
could
overcom
ad
mevalon
synthesi
process
nlink
glycoprotein
transport
initi
site
synthesi
endoplasm
reticulum
cell
variou
golgi
stack
ie
cisgolgi
medial
golgi
transgolgi
final
destin
plasma
membran
lysosom
locat
cell
signal
direct
protein
specif
site
known
case
eg
receptor
lyso
somal
target
elegantli
describ
case
signal
begin
becom
known
nevertheless
number
compound
identifi
perturb
transport
migra
tion
protein
variou
compart
cell
pertub
ionophor
affect
concentr
vari
ou
ion
cellular
compart
may
also
affect
intern
ph
compart
exampl
secret
immunoglobu
lin
plasma
cell
markedli
inhibit
monensin
strike
alter
ultrastructur
appear
golgi
apparatu
seen
suggest
made
deplet
ca
level
ionophor
render
golgi
vesicl
incap
fuse
result
disrupt
flow
glycoprotein
er
golgi
transport
protein
fibronectin
procollagen
also
inhibit
ionophor
transport
variou
viral
envelop
glycoprotein
experi
membran
vacuol
could
visual
electron
microscopi
larg
accumul
procollagen
fibronectin
could
seen
vacuol
immunofluores
one
interest
studi
monensin
use
tool
isol
cisterna
contain
accumul
viral
capsid
sediment
higher
densiti
normal
cisterna
presenc
monensin
termin
glycosyl
inhibit
ie
addit
complex
sugar
galactos
sialic
acid
fucos
etc
incorpor
amino
acid
protein
hydroxyl
prolin
affect
thu
monensintr
cell
newli
synthes
protein
accumul
intracellular
vesicl
appear
deriv
golgi
apparatu
posttransl
modif
block
apparantli
exist
acid
compart
golgi
necessari
secretori
process
recent
discov
vegri
use
antibiot
call
brefeldin
also
inhibit
secret
glycoprotein
hepatocyt
affect
protein
synthesi
brefeldin
inhibit
termin
glycosyl
cproteas
inhibitor
haptoglobulin
well
convers
proalbumin
albumin
modif
appear
occur
transgolgi
hand
proteolyt
process
haptoglobulin
occur
endoplasm
reticulum
modifi
cation
affect
brefeldin
effect
brefeldin
golgi
complex
endoplasm
reticululm
retrovirustransform
murin
erythroleukemia
mel
cell
studi
within
min
addit
compound
stack
cisterna
convert
vesicl
scatter
throughout
centrospher
region
min
golgi
complex
complet
disassembl
next
hour
number
vesi
cle
golgi
area
decreas
concomitantli
expans
predominantli
smooth
endoplasm
reticulum
consist
net
work
dilat
tubul
continu
regular
rer
cisterna
annul
lamella
nuclear
envelop
electron
microscopi
viral
glycoprotein
appear
accumul
membran
immatur
virion
bud
preferenti
cistern
space
find
suggest
brefeldin
block
intracellular
transport
newli
synthes
cellular
viral
protein
immedi
distal
distinct
compart
er
effect
brefeldin
complet
revers
within
short
time
remov
drug
golgi
cisterna
bergan
reappear
cell
free
system
brefeldin
prevent
assembl
nonclathrinco
vesicl
golgi
cisterna
furthermor
coat
vesicl
assembl
block
extens
tubul
network
form
connect
previous
separ
cisterna
stack
singl
topolog
unit
allow
mix
content
golgi
cisterna
studi
consist
vivo
studi
show
earliest
detect
effect
brefeldin
displac
golgi
stack
protein
protein
found
ident
one
major
coat
protein
subunit
cop
golgi
nonclathrinco
vesicl
thu
simpl
explan
effect
interest
use
compound
act
block
bud
coat
transport
vesicl
brefeldin
wide
use
cell
biolog
biochemistri
use
undoubtedli
provid
import
insight
mechan
protein
transport
golgi
assembl
disa
sembl
indic
earlier
mani
membran
protein
anchor
cell
surfac
glycosylphosphatidylinositol
gpi
anchor
protein
link
carboxyltermin
region
glycan
via
phosphoethanolamin
bridg
sinc
glycan
portion
molecul
essenti
anchor
mechan
inhibitor
glycan
format
consider
interest
determin
role
anchor
mechan
well
understand
function
anchor
protein
discuss
previou
section
manno
syl
residu
anchor
donat
via
dolichylpmannos
inhibi
tor
block
format
glycolipid
affect
anchor
format
thu
amphomycin
effect
cellfre
experi
demonstr
mannosyl
donor
three
mannos
unit
glycan
portion
anchor
inde
dolichylpmannos
sugar
analog
previous
shown
inhibit
dolichylpmannos
format
lipidlink
oligosaccha
ride
also
alter
synthesi
gpianchor
protein
alka
line
phosphatas
cell
caus
accumul
proform
enzym
proform
gradual
process
secretori
form
proteolyt
remov
carboxytermin
hy
drophob
peptid
thu
studi
indic
inhibit
synthesi
dolichylpmannos
block
proteinanchor
assembl
anoth
recent
report
inhibitor
proteinanchor
format
mannosamin
mannosamin
previous
shown
inhibitor
lipidlink
saccharid
format
caus
product
truncat
lipidlink
oligosaccharid
mdck
cell
incub
micromolar
concentr
compound
mannosamin
includ
growth
medium
mdck
cell
block
incorpor
glycosylphosphatidylinositol
gpianchor
pro
tein
thu
polar
mdck
cell
cultur
aminosugar
marked
reduc
appear
cell
surfac
recombin
gpianchor
protein
convert
apic
orient
membran
protein
unpolar
secretori
protein
also
block
surfac
appear
endogen
gpianchor
protein
system
mannosamin
also
inhibit
incorpor
h
ethanolamin
gpianchor
protein
gpi
intermedi
suggest
aminosugar
inhibit
assembl
glycan
portion
anchor
effect
mannosamin
biosynthesi
intermedi
volv
anchor
format
also
examin
mdck
cell
cultur
incub
cell
h
mannos
presenc
variou
amount
mannosamin
aminosugar
inhibit
incorpora
tion
mannos
gpi
intermedi
dosedepend
rever
ibl
manner
mannosamin
shown
incorpor
glycan
mannosamin
probabl
mostli
second
mannos
posit
thu
appear
block
addit
mannos
next
mannos
attach
second
mannos
variou
smaller
size
intermedi
detect
cell
incub
presenc
drug
result
ethanolaminep
could
ad
could
protein
transfer
anchor
inhibi
tion
specif
mannosamin
aminosugar
galactosamin
trehalosamin
inhibitori
studi
mannosamin
inhibitor
becom
known
help
us
understand
physiolog
signific
anchor
mechan
inhibitor
certainli
panacea
biochem
studi
indic
earlier
potenti
problem
utiliza
tion
lack
specif
interfer
key
reaction
nevertheless
provid
valuabl
insight
understand
specif
step
biochem
pathway
well
determin
physiolog
function
variou
biochem
molecul
exampl
term
biosynthesi
nlink
oligosaccharid
inhibi
tor
lipidlink
oligosaccharid
pathway
amphomycin
help
establish
mannosyl
donor
last
four
mannos
residu
glc
man
glcnac
ppdolichol
dolichylpmannos
rather
gdpmannos
inhibitor
path
way
tunicamycin
provid
evid
suggest
carbohydr
portion
asparaginelink
glycoprotein
may
play
number
differ
role
includ
enhanc
stabil
glycoprotein
affect
conform
protein
provid
recognit
signal
target
protein
specif
site
cell
uptak
circul
provid
receptor
molecul
cellcel
adhes
interact
actual
role
carbohydr
depend
amino
acid
sequenc
protein
question
second
group
import
inhibitor
affect
glycosidas
type
enzym
widespread
natur
volv
mani
natur
process
cell
divis
cell
separa
tion
turnov
macromolecul
nlink
glycoprotein
process
thu
inhibitor
enzym
great
potenti
use
biochem
tool
even
therapeut
agent
may
also
lethal
shown
glucosidas
mannosidas
inhibitor
castanospermin
swainsonin
latter
compound
gain
widespread
use
studi
role
carbohydr
nlink
glycoprotein
function
howev
studi
point
need
addit
inhibi
tor
well
structur
differ
inhibitor
studi
glycosidas
inhibitor
shown
even
best
compound
still
somewhat
nonspecif
inhibit
one
enzym
exampl
castanospermin
inhibit
process
enzym
glucosidas
glucosidas
ii
well
lysosom
aglucosidas
glucosidas
swainsonin
somewhat
specif
still
inhibit
mannosidas
ii
lysosom
find
synthes
specif
inhibitor
act
one
enzym
cours
answer
question
known
time
sinc
mechan
catalysi
demonstr
enzym
howev
even
enzym
share
common
catalyt
mechan
still
possibl
narrow
site
action
inhibitor
group
similarli
act
enzym
sinc
sever
inhibitor
appear
distinguish
glucosidas
glucosidas
ii
two
enzym
must
differ
catalyt
mechan
activ
site
thu
studi
provid
hope
specif
obtain
right
inhibitor
find
better
inhibitor
seem
number
approach
could
use
one
logic
cours
would
work
understand
catalyt
mechan
enzym
inhibit
design
inhibitor
base
knowledg
approach
certainli
possibl
like
feasibl
immedi
futur
enzym
involv
biosynthesi
nlink
oligosaccharid
membran
anchor
appear
present
cell
rel
low
abund
therefor
even
purif
enzym
homogen
difficult
actual
sever
protein
purifi
homogen
perhap
modern
approach
molecular
biol
ogi
clone
produc
suffici
amount
crystal
zation
second
approach
design
new
inhibitor
base
structur
alreadi
known
prototyp
regard
variou
laboratori
current
conduct
model
studi
known
inhibitor
provid
basi
develop
analog
alreadyknown
compound
viabl
logic
way
develop
new
inhibitor
one
major
shortcom
approach
provid
complet
new
novel
structur
could
lead
even
better
inhibitor
alreadi
avail
respect
perhap
need
take
lesson
natur
sinc
evolut
million
year
develop
sort
unusu
chemic
structur
unlik
penicillin
streptomycin
bleomycin
name
could
chemic
synthes
de
novo
without
first
hav
ing
isol
character
natur
sourc
thu
third
approach
better
inhibitor
ignor
look
new
inhibitori
compound
natur
sourc
seem
like
like
way
find
new
previous
unknown
structur
